Modeling the economic value of a Chagas’ disease therapeutic vaccine
Volume 8, Issue 9
Purchase or Subscribe
Pages 1293 - 1301http://dx.doi.org/10.4161/hv.20966
: Trypanosoma cruzi
, Chagas’ disease, Chagas’ therapeutic vaccine, Mexico, cost-effectiveness
Authors: Bruce Y. Lee, Kristina M. Bacon, Angela R. Wateska, Maria Elena Bottazzi, Eric Dumonteil and Peter J. Hotez View affiliations
The health burden of Chagas’ disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2–6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas’ therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopathy.
Received: March 6, 2012; Accepted: June 1, 2012; Published Online: August 16, 2012
Full Text - Ahead of Print Available - Log in!